US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Jim Cramer recently endorsed Pfizer, excited by its cancer-fighting potential and robust drug pipeline. A caller praised ...

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...